Magnetic resonance spectroscopy in psychiatry

John D Port, Basant K. Puri

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Introduction Magnetic resonance spectroscopy (MRS) holds great promise for the diagnosis and management of psychiatric disease. The technique has been available for humans since 1973 but was limited to major medical centers where experimental spectroscopy sequences and dedicated support personnel were available, limiting clinical accessibility to researchers rather than clinicians. The advent of commercial clinical spectroscopy software, which was approved by the US Food and Drug Administration in 1995, made clinical MRS widely available, and the number of psychiatric MRS studies proliferated. The increasing interest in psychiatric MRS results from the low sensitivity and specificity shown in most structural imaging studies for detecting psychiatric disease (e.g.,[1]). To date, there are few anatomical markers of psychiatric disease that are considered "reliable." This finding correlates well with the clinical impression that psychiatric diseases are primarily functional, caused by chemical imbalances or microscopic structural differences that are not detectable with current technology. While clinical MR examinations of psychiatric patients are occasionally performed, the clinical indication is usually to rule out any organic causes for the patient’s behavioral anomalies, rather than to make a diagnosis of a particular psychiatric disease.

Original languageEnglish (US)
Title of host publicationClinical MR Neuroimaging: Physiological and Functional Techniques, Second Edition
PublisherCambridge University Press
Pages566-592
Number of pages27
ISBN (Electronic)9781139193481
ISBN (Print)9780521515634
DOIs
StatePublished - Jan 1 2011

Fingerprint

Psychiatry
Magnetic Resonance Spectroscopy
Spectrum Analysis
United States Food and Drug Administration
Disease Management
Mental Disorders
Software
Research Personnel
Technology
Sensitivity and Specificity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Port, J. D., & Puri, B. K. (2011). Magnetic resonance spectroscopy in psychiatry. In Clinical MR Neuroimaging: Physiological and Functional Techniques, Second Edition (pp. 566-592). Cambridge University Press. https://doi.org/10.1017/CBO9781139193481.040

Magnetic resonance spectroscopy in psychiatry. / Port, John D; Puri, Basant K.

Clinical MR Neuroimaging: Physiological and Functional Techniques, Second Edition. Cambridge University Press, 2011. p. 566-592.

Research output: Chapter in Book/Report/Conference proceedingChapter

Port, JD & Puri, BK 2011, Magnetic resonance spectroscopy in psychiatry. in Clinical MR Neuroimaging: Physiological and Functional Techniques, Second Edition. Cambridge University Press, pp. 566-592. https://doi.org/10.1017/CBO9781139193481.040
Port JD, Puri BK. Magnetic resonance spectroscopy in psychiatry. In Clinical MR Neuroimaging: Physiological and Functional Techniques, Second Edition. Cambridge University Press. 2011. p. 566-592 https://doi.org/10.1017/CBO9781139193481.040
Port, John D ; Puri, Basant K. / Magnetic resonance spectroscopy in psychiatry. Clinical MR Neuroimaging: Physiological and Functional Techniques, Second Edition. Cambridge University Press, 2011. pp. 566-592
@inbook{ed7f6cac992c40eea9385d70eb676ccf,
title = "Magnetic resonance spectroscopy in psychiatry",
abstract = "Introduction Magnetic resonance spectroscopy (MRS) holds great promise for the diagnosis and management of psychiatric disease. The technique has been available for humans since 1973 but was limited to major medical centers where experimental spectroscopy sequences and dedicated support personnel were available, limiting clinical accessibility to researchers rather than clinicians. The advent of commercial clinical spectroscopy software, which was approved by the US Food and Drug Administration in 1995, made clinical MRS widely available, and the number of psychiatric MRS studies proliferated. The increasing interest in psychiatric MRS results from the low sensitivity and specificity shown in most structural imaging studies for detecting psychiatric disease (e.g.,[1]). To date, there are few anatomical markers of psychiatric disease that are considered {"}reliable.{"} This finding correlates well with the clinical impression that psychiatric diseases are primarily functional, caused by chemical imbalances or microscopic structural differences that are not detectable with current technology. While clinical MR examinations of psychiatric patients are occasionally performed, the clinical indication is usually to rule out any organic causes for the patient’s behavioral anomalies, rather than to make a diagnosis of a particular psychiatric disease.",
author = "Port, {John D} and Puri, {Basant K.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/CBO9781139193481.040",
language = "English (US)",
isbn = "9780521515634",
pages = "566--592",
booktitle = "Clinical MR Neuroimaging: Physiological and Functional Techniques, Second Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Magnetic resonance spectroscopy in psychiatry

AU - Port, John D

AU - Puri, Basant K.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Introduction Magnetic resonance spectroscopy (MRS) holds great promise for the diagnosis and management of psychiatric disease. The technique has been available for humans since 1973 but was limited to major medical centers where experimental spectroscopy sequences and dedicated support personnel were available, limiting clinical accessibility to researchers rather than clinicians. The advent of commercial clinical spectroscopy software, which was approved by the US Food and Drug Administration in 1995, made clinical MRS widely available, and the number of psychiatric MRS studies proliferated. The increasing interest in psychiatric MRS results from the low sensitivity and specificity shown in most structural imaging studies for detecting psychiatric disease (e.g.,[1]). To date, there are few anatomical markers of psychiatric disease that are considered "reliable." This finding correlates well with the clinical impression that psychiatric diseases are primarily functional, caused by chemical imbalances or microscopic structural differences that are not detectable with current technology. While clinical MR examinations of psychiatric patients are occasionally performed, the clinical indication is usually to rule out any organic causes for the patient’s behavioral anomalies, rather than to make a diagnosis of a particular psychiatric disease.

AB - Introduction Magnetic resonance spectroscopy (MRS) holds great promise for the diagnosis and management of psychiatric disease. The technique has been available for humans since 1973 but was limited to major medical centers where experimental spectroscopy sequences and dedicated support personnel were available, limiting clinical accessibility to researchers rather than clinicians. The advent of commercial clinical spectroscopy software, which was approved by the US Food and Drug Administration in 1995, made clinical MRS widely available, and the number of psychiatric MRS studies proliferated. The increasing interest in psychiatric MRS results from the low sensitivity and specificity shown in most structural imaging studies for detecting psychiatric disease (e.g.,[1]). To date, there are few anatomical markers of psychiatric disease that are considered "reliable." This finding correlates well with the clinical impression that psychiatric diseases are primarily functional, caused by chemical imbalances or microscopic structural differences that are not detectable with current technology. While clinical MR examinations of psychiatric patients are occasionally performed, the clinical indication is usually to rule out any organic causes for the patient’s behavioral anomalies, rather than to make a diagnosis of a particular psychiatric disease.

UR - http://www.scopus.com/inward/record.url?scp=85011350054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011350054&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139193481.040

DO - 10.1017/CBO9781139193481.040

M3 - Chapter

AN - SCOPUS:85011350054

SN - 9780521515634

SP - 566

EP - 592

BT - Clinical MR Neuroimaging: Physiological and Functional Techniques, Second Edition

PB - Cambridge University Press

ER -